People can view the slides even if they dont have powerpoint, but they cant. Erythropoiesis stimulating agents esas this article contains instructions for coding medical necessity in accordance with both the national coverage determination ncd and local coverage determination lcd and other cms instructions on darbepoetin alfa aranesp, dpa and epoetin alfa epogen, procrit, epo. Information on erythropoiesisstimulating agents esa epoetin alfa marketed as procrit, epogen, darbepoetin alfa marketed as aranesp aranesp medication guide pdf. Erythropoiesisstimulating agents should be discontinued after 6 to 8 weeks in nonresponders. Pdf erythropoietin stimulating agents in the management. Erythropoiesis stimulating agents esas in cancer and related neoplastic conditions ncd 110.
Caution should be exercised when using esas with chemotherapeutic agents in diseases associated with. Decision memo for erythropoiesis stimulating agents esas for non. In these situations they decrease the need for blood transfusions. E poetin alfa and darbepoetin alfa are erythropoiesisstimulating agents esas, approved for the treatment of anemia low red blood. Medicare cd medical coverage policy erythropoietin. The maximum dosage of erythropoietin should not exceed a total of 60,000 units per week 5. Due to inconsistencies between the drug labels on dailymed and the pill images provided by rximage, we no longer display the rximage pill images associated with drug labels we anticipate reposting the images once we are able identify and filter out images that do not match the information provided in. Use this page to view the contact information, documents, and history of considerations for the national coverage analysis nca for erythropoiesis stimulating agents.
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease article pdf available in patient preference and adherence 2. Treatment with erythropoiesisstimulating agents has been used for the anemia of mds for almost 25 years. Dailymed search results for erythropoiesisstimulating agent. Erythropoiesisstimulating agents clinical criteria information included in this document erythropoiesisstimulating agents aranesp drugs requiring prior authorization. If approved, authorizations will be valid for a time period of up to 12 months. The kidney is the primary site of erythropoietin production in adults ratcliffe et al 1995.
In renal anemia, esas act as hormonereplacement therapy substituting for the loss of production of endogenous erythropoietin. This medical policy is not intended to dictate to providers how to practice medicine. Therefore, please ensure that this first page, hgbesa assessment, is. Ed hematocrit level has exceeded 39% or hemoglobin level has exceeded. June 24, 2011 the us food and drug administration fda today urged more conservative dosing guidelines for erythropoiesisstimulating agents. Regulation of platelet count by erythropoiesisstimulating agents iron axis in hemodialysis patients kiyomi koike,1,2 kei fukami,1 atsushi kawaguchi,2 kazumasa shimamatsu,3 shoichi yamagishi,4 seiya okuda1 1division of nephrology, department of medicine, kurume university school of medicine, kurume, 2the biostatistics center, kurume university, kurume, 3shimamatsu naika iin clinic. Medical policy revisions erythropoietin stimulating agents. Erythropoietin clinical trials, 944 results, page 1. Therapeutic class overview erythropoiesisstimulating agents. Benefits and risks in supportive care of cancer article pdf available in current oncology 15suppl 1. Thi form must be submitted obtain a prior authorization for an erythropoietin stimulating agent epogen, procrit or aranesp. At, we keep tabs on over 200,000 clinical trials in the us and abroad, using medical data supplied directly by the us national institutes of health.
The authors have completed the unified competing interest form at. The protocol works as a complete package, however, it is to be used in a sequential order. Erythropoietin stimulating agents esa request form instructions. Interpretation of blood tests and appropriate dose adjustments remains the responsibility of the renal unit. The role of erythropoiesisstimulating agents in esrd. Anemia secondary to myelodysplastic syndrome mds o treatment of lower risk disease associated with symptomatic anemia. Erythropoiesis stimulating agents esa fax or mail this completed form for rx fax. Gs dosage of erythropoietin stimulating agent has been reduced and maintained in response to hematocrit or hemoglobin level. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in hivaids. Erythropoetin stimulating agents for the treatment for. Incomplete forms will be returned for additional information.
Restricted use of erythropoiesisstimulating agent is safe. No data are available on the combined use of epo, gcsf and tpo in mds and should not be used in routine daily practice. Who eml 20162017 application for erythropoietinstimulating agents erythropoietin type blood factors pdf. All three erythropoiesisstimulating agents the two recombinant erythropoietins epogen and procrit and the.
See the medicare benefit policy manual, chapter 11, section 90 and chapter 15, section 50. Used for an anemic patient with renal failure epoetin alfa is the synthetic form of erythropoietin and is a hormone produced by the kidneys. Nothing in this medical policy is intended to discourage or prohibit providing other medical advice or treatment. As shown in table 2, epo deficiency is by far the leading cause of anemia in patients with ckd. They work by increasing red blood cells in the blood. Erythropoiesisstimulating agents aranesp, epogen, procrit preauthorization request physician fax form only the prescriber may complete and fax this form. Recombinant erythropoietin is a manmade version of natural erythropoietin. Throuvalas n, antonadou d, boufi m, lavey r, malamos n. Erythropoetin definition of erythropoetin by medical. Erythropoietin definition of erythropoietin by medical. Esas are biologically engineered hormones produced by recombinant dna technology.
Erythropoietin may increase hypertension patients with chronic kidney disease. The following documentation is required for preauthorization. A wide range of erythropoiesisstimulating agents to stimulate red blood cell production are currently in clinical use, but advances in our understanding of erythropoiesis have provided an ever. Erythropoiesisstimulating agents prices and information. Erythropoietin stimulating agents in the management of. Erythropoiesis stimulating agents esas in cancer and. Erythropoiesisstimulating agents esas include recombinant erythropoietic. These drugs are given by injection shot and work by. Accessing pdf documents with assistive technology a. Erythropoietin analogs contain the identical amino acid sequence as naturally occurring erythropoietin, and have the same biological effect. These drugs are given by injection shot and work by stimulating the production of more red blood cells. Epo, also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidney in response to cellular hypoxia. Erythropoietin stimulating agents esas 3 erythropoietin directly and other causes of anemia have been ruled out. Erythropoiesis stimulating agents 2 high risk for perioperative transfusions with significant, anticipated blood loss, for example, for patients expected to lose greater than two units of blood.
The goal of this activity is to provide healthcare providers with foundational knowledge on the physiology of erythrocyte production in the body, the development of erythropoiesisstimulating agents esas, and how emerging esas aid this natural process. The patient in renal failure does not have typical kidney function and therefore may have this medication prescribed to treat anemia associated with the lack of natural production of the hormone. Regulation of platelet count by erythropoiesisstimulating. Erythropoiesisstimulating agents esa are medications which stimulate the bone marrow to make red blood cells. Internal only renal department, revised 20 page 1 of 4 erythropoietin stimulating agents indications for use. Demonstrated benefits of esa s include lower rates of transfusion and improved qol, including reduced fatigue and better cognition. The dose frequency, depending on the patients condition, can vary from once in a week or once every two weeks. The original intent of our analysis was to evaluate risks for vte when cancer patients received esas vs placebocontrol. Compare pdfs, how to compare pdf files adobe acrobat dc. Erythropoiesisstimulating agents esa are medications which stimulate the bone marrow to. What links here related changes upload file special pages permanent link page information. Reimbursement policy erythropoietin stimulating agent esa level of less than 500 muml are more likely to respond to erythropoiesisstimulating agent esa therapy.
This chart is created by aggregating the total number of claims for the drugs in this class divided by. Increasing incidence of anemia cases worldwide is driving the growth of. The erythropoiesisstimulating agents esas epoetin alfa and darbepoetin are indicated for the treatment of anemia caused by endstage renal disease esrd, zidovudine therapy in patients with hiv, chemotherapy in cancer patients, and also to reduce transfusion need in patients scheduled for noncardiac major surgery. Studies utilizing transgenic mice suggest that a population of interstitial fibroblasts also known as the type i interstitial cell are the major source of renal erythropoietin. Erythropoiesisstimulating agents in the treatment of. Reimbursement policy erythropoiesis stimulating agents. Benefits and harms of erythropoiesisstimulating agents for anemia related to cancer. For medicare advantage bluemedicare hmo and ppo plans. Epoetin beta is an erythropoiesisstimulating agent esa indicated for the treatment of anemia associated with chronic kidney disease ckd in adult patients on dialysis and patients not on dialysis. Erythropoiesis stimulating agents medical clinical.
You can easily compare, summarize, and visualize changes between documents. Erythropoiesis stimulating agents and other growth factors. Erythropoiesis stimulating agents injectable medication. Erythropoetin stimulating agents for the treatment for renal anaemia information for primary care management of renal anaemia is coordinated by the anaemia nurse practitioner based at hull and east yorkshire hospitals nhs trust. Compliance with the provisions of erythropoiesis stimulating agents may be monitored and. Do erythropoiesisstimulating agents have a risk evaluation and. Use of erythropoiesisstimulating agents for anemia related to cancer may increase mortality. We retrospectively analyzed the outcome of dialysis.
Dosing, uses, side effects, interactions, patient handouts, pricing and more from medscape reference. All area s must be completed in order to proces the request. Reimbursement policy erythropoietin stimulating agent esa. This user guide provides guidance on accessing portable document format pdf documents for blind and visually impaired users of screen reading technology.
Covered chronic diseases include, rheumatoid arthritis, systemic lupuserythematosis, chronic hepatitis c, crohns disease and ulcerative colitis. The use of when the hemoglobin is less than 9 g per deciliter may increase the risk of stroke according to a randomized controlled trial. This hormone is called erythropoietin and it controls the production of red blood cells in the body. Why is dailymed no longer displaying pill images on the search results and drug info pages. The purpose of this medical policy is to provide a guide to coverage. It is produced by cloning the gene for erythropoietin. Recombinant erythropoietin drugs are known as erythropoietinstimulating agents esas. An erythropoietin stimulating agent esa is an analog of erythropoietin. Approved september 18, 20 medical policy revisions erythropoietin stimulating agents esas updated the name of the policy. Learn how to compare two pdf files using adobe acrobat dc.
Description of procedure or service endogenous erythropoietin epo is a glycoprotein hematopoietic growth factor synthesized at the. Erythropoiesisstimulating agents esas increase red blood cell rbc production in bone marrow by activating the erythropoietin receptor. January 1, 2020 page 2 of 6 aranesp is covered for the following indications. S105 february 2008 with 46 reads how we measure reads. The effect of erythropoiesisstimulating agent esa on dialysis initiation in advanced chronic kidney disease ckd patients is not clear. Guiding principles for the quality use of offlabel. Erythropoiesis stimulating agents esas boost the production of red blood cells and as such may play a role in optimising red cell mass pbm pillar 1 in specific groups of patients. Key messages y esas are a method of optimising red cell mass pbm pillar 1 y esas are an authority item on the pharmaceutical benefits scheme pbs with a limited. New dosing guidelines for erythropoiesisstimulating agents.
Red blood cells are needed to carry oxygen to all parts of the body. Local medicare contractors may continue to make reasonable and necessary determinations on all other uses of esas not specified in this ncd. Erythropoiesisstimulating agents market global industry. Save powerpoint presentations as pdf files office support. These agents are given as subcutaneous injections or as intravenous injections.